FAERS Safety Signals for Perfluorohexyloctane Ophthalmic Solution, Q4 2023–Q4 2024

Zhengtai Sun conducted a retrospective pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS) database from the fourth quarter of 2023 through the fourth quarter of 2024. The study identified 92 adverse event reports associated with perfluorohexyloctane ophthalmic solution for dry eye disease. It employed four disproportionality analysis methods to identify potential safety signals, with a median time-to-onset for adverse events of 2 days.

Use Cases

• Identify potential safety signals for a novel dry eye treatment based on disproportionality analysis methods mentioned in the description.
• Analyze the time-to-onset profile of adverse events based on the reported median of 2 days.
• Study the nature of reported adverse events, such as those related to the product delivery mechanism or administration schedule, as detailed in the results.
• Support risk management and long-term treatment strategies for dry eye disease based on real-world evidence from the FAERS database.

Strengths

• Analysis is based on a recognized pharmacovigilance database (FAERS).
• Employs four established disproportionality analysis methods (ROR, PRR, BCPNN, MGPS).
• Provides specific metrics, including 92 adverse event reports and a median time-to-onset of 2 days.

Limitations

• Row count for the underlying data is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small (14.3 KB), indicating limited scope.

Provenance

Source

FDA Adverse Event Reporting System (FAERS) database.

Collection Method

Retrospective pharmacovigilance study using disproportionality analysis.

Time Range

Fourth quarter of 2023 through the fourth quarter of 2024.

Freshness

Last updated 2026-05-28 04:48:11; freshness should be verified.